Immix Biopharma, Inc. (IMMX)

NCM – Цена в реальном времени. Валюта: USD

10.66

+0.74 (7.46%)

При закрытии: May 12, 2026, 4:00 PM EDT

10.56

-0.10 (-0.94%)

До открытия: May 13, 2026, 5:04 AM EDT

09.04.2026

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.

$Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones$

30.03.2026

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission –

03.03.2026

Immix Biopharma to Participate in Upcoming Investor Conferences

LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences:

28.01.2026

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting –

11.12.2025

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma (IMMX) is advancing NXC-201, a one-time CAR T therapy for AL amyloidosis, showing 95% complete/near-complete response rates and superior safety. IMMX's recent $100 million financing removes capital overhang, strengthens negotiating position, and supports a clear path toward BLA submission in mid-2026. With reasonable peak revenue scenarios ranging from $320 million to over $1 billion annually, the current sub-$400 million valuation presents further upside.

09.12.2025

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $93.7 million.

07.12.2025

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $100 million. The offering is expected to close on or about December 9, 2025, subject to the satisfaction of customary closing conditions.

Видео

No Data

There is no data to display

Пресс-релизы

$Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones$

30.03.2026

Immix Biopharma, Inc. (IMMX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Immix Biopharma, Inc. (IMMX)

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma to Participate in Upcoming Investor Conferences

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Видео

No Data

Пресс-релизы

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma to Participate in Upcoming Investor Conferences

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Видео

No Data

Пресс-релизы

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Search stocks

Immix Biopharma, Inc. (IMMX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Immix Biopharma, Inc. (IMMX)

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma to Participate in Upcoming Investor Conferences

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Видео

No Data

Пресс-релизы

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma to Participate in Upcoming Investor Conferences

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Видео

No Data

Пресс-релизы

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants